Takeda Pharmaceutical Co. has licensed exclusive rights to use ImmunoGen’s ADC technology to develop and commercialize targeted anticancer therapeutics for as many as two undisclosed targets. Takeda has the option to take a license for a third target for an additional upfront fee.   ImmunoGen will receive $20 million upfront, and for each target, is eligible to receive milestone payments of as much as $210 million plus royalties on sales of any resulting ADC products. Takeda is responsible for t...